Our team is developing a ground-breaking tool for identifying beta-amyloid (AB) plaques, a key biomarker of Alzheimer's disease. Imagine the impact this will have on finding a cure.

Detecting Alzheimer

As an extension of the central nervous system, the eye is a window to the brain

The retina is a light-sensitive layer of tissue that lines the back of the eye. Attached directly to the brain, it’s not surprising that the eye provides accurate insights into neurological pathologies.

With the collection of sequential images of the retina, healthcare professionals and researchers are able to obtain monochromatic illumination wavelengths to build a hyperspectral cube of data. While providing a method for observing anatomical structures, this process also paves the way for an in-depth understanding of patient data through the use of spectral signatures – a breakthrough in localizing and quantifying specific biomolecules in the fundus.


Hyperspectral Imaging


Optina Diagnostics’ hyperspectral camera collects and processes the light intensity for a large number (100-200) of contiguous spectral bands at very high speeds. Every pixel in an image contains a continuous spectrum (in radiance or reflectance) where this vital information is then used to characterize biomarkers in the fundus with greater precision than ever before.

Alzheimer’s is the 6th leading cause of
death in the US.

The experts

Optina Diagnostics is made up of a driven and dynamic team of experts in the areas of business development, research, and finance.

David Lapointe, M. Sc.

President and CEO

Chantal Miklosi


Jean-Philippe Sylvestre, ing., M.Sc., Ph.D.


Claudia Chevrefils, ing., Ph.D.


Faten M’hiri, Ph.D.

Scientific Team

Reza Jafari, Ph.D.

Scientific Team

Marie-Andrée Tremblay, ing.

Scientific Team

Anne-Marie Bédard

Clinical Study Manager

Sébastien Blais Ouellette, Ph.D.

Board of Directors

Jean Daniel Arbour

Board of Directors